Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Napp Gets Authorization for REZZAYO® in Great Britain for Invasive Candidiasis Treatment
Details : Rezzayo (rezafungin) is a novel once-weekly echinocandin, a 1,3-beta-glucan synthase inhibitor. It is approved for the treatment of invasive candidiasis.
Product Name : Rezzayo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2024
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The European Commission approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy c...
Product Name : Invokana
Product Type : HPAPI
Upfront Cash : Inapplicable
July 02, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on a conclusive signal of efficacy in the prevention of the prim...
Product Name : Invokana
Product Type : HPAPI
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Recipient : Research in Real-Life
Deal Size : Inapplicable
Deal Type : Inapplicable
A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down
Details : Fluticasone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2015
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Recipient : Research in Real-Life
Deal Size : Inapplicable
Deal Type : Inapplicable